# DESCRIPTION

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND OF THE INVENTION

- motivate receptor mediated targeted drug delivery
- describe limitations of systemic delivery
- discuss oral administration of therapeutics
- summarize attempts to develop oral drug delivery systems
- describe nanoparticle-based therapeutics
- discuss limitations of nanoparticle administration
- motivate need for oral nanoparticle administration
- state objects of the invention

## SUMMARY OF THE INVENTION

- introduce receptor-targeted nanoparticles
- describe selective delivery to tissues
- summarize nanoparticle composition
- discuss targeting moieties and receptors
- describe nanoparticle formulation and release
- list representative selective receptors
- summarize methods of making and using R-targeted nanoparticles

## DETAILED DESCRIPTION OF THE INVENTION

- introduce R-targeted nanoparticles

### I. Definitions

- define treating or preventing
- define bioactive agent
- define sufficient and effective
- define biocompatible
- define pharmaceutically acceptable
- define small molecule
- define molecular weight
- define copolymer
- define biodegradable
- define hydrophilic
- define hydrophobic
- define lipophilic
- define amphiphilic
- define mean particle size
- define monodisperse
- define targeting moiety
- define mediated transport
- define transcytosis and endocytosis

### II. Receptor-Targeted Nanoparticles

- introduce receptor-targeted nanoparticles
- describe particle core composition
- specify polymeric particle core
- list biodegradable polymers
- describe non-biodegradable polymers
- mention excipients for altering core properties
- introduce hydrophilic polymers
- list examples of hydrophilic polymers
- introduce hydrophobic polymers
- list examples of hydrophobic polymers
- specify aliphatic polyester
- describe molecular weight of hydrophobic polymer
- introduce amphiphilic polymer
- describe block copolymers
- mention PEGylation
- describe copolymers containing poly(ester-ether)s
- introduce amphiphilic compounds
- list examples of phospholipids
- specify molecular weight of amphiphilic lipid
- describe lipid particle core
- introduce lipid nanoparticles
- describe lipid micelles
- introduce microemulsions
- describe liposomes
- specify types of liposomes
- describe aqueous center of lipid micelles and liposomes
- list suitable alcohols for aqueous center
- conclude particle core description
- introduce receptor-targeted nanoparticles
- describe solid lipid particles
- list suitable neutral and anionic lipids
- list suitable cationic lipids
- describe inorganic particles
- list suitable metals for inorganic particles
- list suitable metal oxides for inorganic particles
- describe hybrid particles
- describe polymer-stabilized liposomes
- describe polymer-stabilized solid lipid particles
- describe polymer-stabilized inorganic particles
- list suitable lipophilic polymers
- introduce transport mediating receptors
- describe FcRn receptor
- describe FcRn-mediated transcytosis
- list representative receptors and tissues
- describe Fc-targeted nanoparticles
- describe FcRn binding moiety
- describe cleavable linkers
- describe additional targeting moieties
- describe targeting ECM
- describe collagen IV targeting
- describe other targeting moieties
- describe FcRn receptor isolation
- describe FcRn receptor characterization
- describe FcRn binding moiety identification
- describe protein or peptide FcRn binding moieties
- describe immunoglobulin FcRn binding moieties
- describe aptamer FcRn binding moieties
- describe spiegelmer FcRn binding moieties
- describe RNAi-inducing entity FcRn binding moieties
- describe small molecule FcRn binding moieties
- describe carbohydrate FcRn binding moieties
- describe lipid FcRn binding moieties
- describe other FcRn binding moieties
- conclude receptor-targeted nanoparticles
- define FcRn binding moiety
- specify FcRn binding moiety as Fc fragment
- specify FcRn binding moiety as Fc fragment of IgG antibody
- provide sequence of Fc portion of human IgG 1 antibody
- provide nucleic acid sequence corresponding to Fc portion of human IgG 1 antibody
- specify homology of FcRn binding moiety to Fc portion of IgG antibody
- specify homology of FcRn binding moiety to SEQ ID NOs.: 1-6
- describe FcRn binding moiety as portion of Fc fragment
- specify binding ability of FcRn binding moiety
- describe modification of FcRn binding moiety to reduce immunogenicity
- describe modification of FcRn binding moiety to avoid binding to complement systems
- describe use of non-FcRn receptor binding moiety
- specify non-FcRn receptor as adhesion molecule
- provide examples of adhesion molecules
- describe conjugation of FcRn binding moiety and non-FcRn receptor binding moiety
- describe targeting of nanoparticulate formulation to receptors for transport across tissue
- specify receptors for transport across tissue
- describe binding of FcRn targeting moieties to nanoparticle
- specify covalent binding of FcRn targeting moieties to nanoparticle
- describe density of FcRn targeting moieties on nanoparticle surface
- introduce therapeutic, prophylactic, and diagnostic agents
- describe use of nanoparticles for treating diseases
- specify examples of therapeutic agents for treating hypertension, heart failure, and renal conditions
- specify examples of therapeutic agents for treating lung diseases
- specify examples of radiopharmaceuticals for diagnosing and/or treating lung cancer or bronchial dysplasia
- describe use of nanoparticles for mucosal vaccination
- describe use of nanoparticles for oral or intranasal immunization
- introduce receptor-targeted nanoparticles
- list active agents for diagnosis or imaging methods
- list anti-cancer active agents
- list analgesic active agents
- describe conjugating IgG Fc fragments to NP surface
- explain receptor-mediated transcytosis
- describe loading range for agent within particles
- explain drug delivery system targeting receptors
- describe NP formulation for mucosal vaccination
- explain ability of NPs to enter systemic circulation
- list organs reached by NPs after oral administration
- describe therapeutic agents for treating hypertension
- list functional classes of drugs for treating hypertension
- list suitable drugs for treating hypertension
- describe NP distribution to lungs after oral administration
- list therapeutic agents for treating lung cancer or bronchial dysplasia
- describe radiopharmaceuticals for diagnosis or therapy
- list anti-cancer active agents
- list alkylating agents
- list antimetabolites
- list natural products
- list hormones and antagonists
- list miscellaneous agents
- describe immunosuppressive drugs
- describe insulin or insulin analogs
- describe dosages of insulin
- list types of commercial insulin
- describe fast acting insulins
- describe more concentrated forms of insulin
- describe rapid-acting insulin analogs
- describe intermediate-acting insulin
- describe blends of immediate acting insulin and intermediate acting insulin
- describe long acting insulins
- describe insulin glargine
- describe insulin detemir
- explain extended duration of action of LANTUS
- describe difference between insulin glargine and human insulin
- conclude NP formulation for oral administration

### III. Methods of Making R-targeted Nanoparticles

- introduce methods of making nanoparticles
- describe nanoparticle shapes
- describe nanoparticle properties
- introduce polymer-drug conjugates
- discuss factors for synthesis of polymer-drug conjugates
- mention alternative reactions for preparation of polymer-drug conjugates
- introduce polymeric particle core
- describe spray drying method
- describe phase separation encapsulation method
- describe spontaneous emulsion nanoencapsulation
- describe solvent evaporation nanoencapsulation
- describe solvent removal nanoencapsulation
- describe phase inversion nanoencapsulation
- introduce lipid particle core
- describe high pressure homogenization method
- describe hot homogenization
- describe cold homogenization
- describe ultrasonication/high speed homogenization method
- describe solvent evaporation method
- describe solvent emulsification-diffusion method
- describe supercritical fluid method
- describe microemulsion based method
- describe spray drying method for lipid particles
- introduce inorganic particle core
- describe physical preparation methods
- describe chemical preparation methods
- describe thermolysis method
- describe stabilization of inorganic particles
- describe microfluidics method
- introduce receptor targeting moieties
- describe non-covalent attachment of targeting moieties
- describe covalent attachment of targeting moieties
- describe modification of targeting moieties with thiol group
- describe reaction of targeting moieties with maleimide group
- describe covalent attachment of targeting moieties to materials
- describe modification of materials with thiol group
- describe reaction of materials with maleimide group
- describe use of multiple receptors on particle surface
- describe use of FcRN receptor for targeting delivery
- describe use of transferrin receptor for transcytosis
- describe avoidance of transferrin receptor binding to albumin
- describe passage through blood brain barrier

### IV. Compositions and Formulations of R-Targeted Nanoparticles

- describe formulations
- enteral administration routes
- enteral dosage forms
- prepare tablets using compression/molding
- prepare capsules using gelatin/non-gelatin shells
- use pharmaceutically acceptable carriers
- list hydrophobic/hydrophilic polymers
- list coating composition components
- prepare delayed release dosage forms
- reference pharmaceutical dosage form texts
- list optional pharmaceutically acceptable excipients
- describe diluents
- describe binders
- describe lubricants
- describe disintegrants
- describe stabilizers
- list diluents
- list binders
- list lubricants
- list disintegrants
- list stabilizers
- describe coating materials
- describe coating weights
- describe extended release dosage forms
- describe diffusion/osmotic systems
- describe matrix devices
- list matrix device materials
- describe osmotic systems
- describe semi-permeable coatings
- describe multiple unit systems
- add immediate release portion
- prepare extended release tablets
- describe tablet formulations
- describe wax materials
- prepare delayed release dosage forms
- describe coating materials
- describe coating weights
- describe coating composition additives
- describe methods for preparing drug-containing tablets/beads
- reference pharmaceutical dosage form texts

### V. Methods of Using R-targeted Nanoparticles and Compositions and Formulations Thereof

- introduce nanoparticles for disease treatment
- limitations of parenteral administration
- need for oral administration
- intestinal absorption inefficiency
- discovery of receptor-mediated transport
- FcRn receptor and IgG Fc molecules
- FcRn expression in intestine and other tissues
- pH-dependent binding of FcRn and IgG
- conjugation of IgG Fc fragments to NP surface
- receptor-mediated transport of NP-Fc
- intracellular trafficking and exocytosis
- NP-Fc release into systemic circulation
- distribution to various organs
- treatment of diseases with NP-Fc
- selection of receptors for tissue targeting
- list of receptors for various tissues
- administration routes and formulations
- targeted delivery to heart, skeletal muscle, or adipose tissue
- targeted delivery to testis tissue
- targeted delivery to brain tissue
- targeted delivery to intestine tissue
- targeted delivery to liver tissue
- targeted delivery to kidney tissue
- targeted delivery to placenta tissue
- targeted delivery to lung tissue
- targeted delivery to mammary gland tissue
- targeted delivery to thyroid tissue
- targeted delivery to genitourinary tract tissue
- transport across biological barriers

## EXAMPLES

- introduce animal studies

### Example 1

- describe FcRn expression in wild-type mice
- detail western blot analysis
- describe immunohistochemistry
- present results

### Example 2

- describe preparation of Fc-targeted nanoparticles
- detail PLA-PEG-MAL synthesis
- describe nanoprecipitation self-assembly method
- detail Fc conjugation to nanoparticles
- describe particle characterization
- present results of nanoparticle characterization
- present results of Fc conjugation

### Example 3

- describe in vitro transepithelial transport study
- detail Caco-2 cell monolayer model
- describe 3H-labeled nanoparticle preparation
- detail transport experiment
- present results of transport study
- describe blocking experiment

### Example 4

- describe in vivo absorption and biodistribution study
- detail 14C-labeled nanoparticle preparation
- describe biodistribution experiment
- detail tissue harvesting and analysis
- present results of biodistribution study
- describe oral absorption efficiency calculation
- present results of oral absorption efficiency
- describe fluorescently labeled nanoparticle preparation
- detail in vivo transport visualization
- present results of in vivo transport visualization

### Example 5

- describe oral insulin delivery study
- detail insulin nanoparticle preparation
- describe insulin encapsulation measurement
- detail insulin release study
- present results of insulin release study
- describe bioactivity study
- present results of bioactivity study
- describe oral administration study
- present results of oral administration study
- describe control group studies
- present results of control group studies

### Example 6

- test FcRn role in NP transport

### Example 7

- evaluate dose dependency

